Uncategorized-EN
INVINCIBLE-3: Intratumorally administered INT230-6 in advanced soft tissue sarcomas
A multicenter, randomized, phase III study to assess the efficacy and safety of intratumorally administered INT230-6 in locally recurrent, inoperable or metastatic soft tissue sarcomas. Agents: INT230-6 Phase III Status Open, recruiting Sponsor Intensity Therapeutics, Inc. Further information: https://www.clinicaltrials.gov/study/NCT06263231 WHO is the trial for? Adult patients with the following subtypes of soft tissue…
Read MoreReflecting on 2024: A Special Year for SPAGN
The year of the 15th anniversary of SPAGN has been a great success full of projects and partnerships for the benefit of sarcoma patients. 2024 showcases the wonderful development of the network since its creation. Our Chief Executive Kathrin Schuster looks back at the year with pride and sends a big thank you to all members, supporters and colleagues!
Read MoreThe story behind the Sarcoma of the Year
World sarcoma specialists discussed recently latest developments in treatments of dedifferentiated liposarcoma, or DDLPS, an aggressive and rare type of cancer. They gathered at the annual conference of the Connective Tissue Oncology Society (CTOS) in San Diego (USA) from 13 to 16 November 2024. Expectations were high on studies ongoing, but for most patients and patient advocates the intricacies of what is special about dedifferentiated liposarcoma are not easy to grasp. Professor Robin Jones, medical oncologist specializing in sarcomas, gives some insights in an interview with Gabi Ott, Editor-in-Chief of the Voices of Sarcoma blog.
Read MoreIAG933 in solid tumors incl. EHE
Trial name: IAG933 in Advanced Solid Tumors incl. EHE Agents: IAG933 Phase I Status Recruiting Sponsor Novartis Pharmaceuticals This is a phase I, open-label, multi-center study of IAG933 to assesss the safety and tolerability as well as anti-tumor activity in certain patient populations. This includes patients with epithelioid hemangioendothelioma (EHE). Further information can…
Read MoreAVA6000 in advanced solid tumors incl. soft tissue sarcomas
Trial name: ADC AVA6000 in Advanced Solid Tumors Agents: AVA6000 Phase I Status Recruiting Sponsor Avacta Life Sciences Ltd This phase I study evaluates the safety, tolerability, pharmacokinetics (PK) and early efficacy of AVA6000 in patients with locally advanced and/or metastatic solid tumours incl. soft tissue sarcomas. Further information can be found on…
Read MoreM3554 in advanced solid tumors incl. soft-tissue sarcomas
Trial name: Anti-GD2 ADC M3554 in Advanced Solid Tumors Agents: M3554 Phase I Status Recruiting Sponsor EMD Serono Research & Development Institute, Inc. This Phase I trial is testing the safety, dosage, and effectiveness of a new targeted therapy, M3554, for people with advanced cancers incl. soft tissue sarcomas. Further information can be…
Read MoreEMERGE 101: Lurbinectedin in Ewing Sarcoma (kids & young adults)
Trial name: EMERGE 101: Lurbinectedin in Ewing’s Sarcoma Agents: Lurbinectedin Phase I/II Status Recruiting Sponsor Jazz Pharmaceuticals This phase I/II study evaluates the safety, efficacy, and optimal dosing of lurbinectedin in pediatric and young adult patients with previously treated recurrent or refractory Ewing sarcoma. Further information can be found on clinicaltrials.gov. WHO…
Read MoreDS-2243a in advanced solid tumors incl. synovial sarcoma or myxoid/round cell liposarcoma
First-in-human trial of DS-2243a in participants with advanced solid tumors Agents: DS-2243a Phase I Status Open, recruiting Sponsor Daiichi Sankyo Further information: https://clinicaltrials.gov/study/NCT06644755 This study evaluates safety, tolerability, and efficacy of DS-2243a as a treatment for participants with advanced solid tumors incl. synovial sarcoma and myxoid/round cell liposarcoma. WHO is the trial…
Read MoreGlobal Insights on Sarcoma Diagnosis: Preliminary Findings from SPAGN’s Survey
The Sarcoma Patients Advocacy Global Network (SPAGN) is shedding light on the complex and often lengthy journey to a correct sarcoma diagnosis through its Global Survey on Sarcoma Diagnosis Pathways. This initiative aims to capture real-world patient experiences worldwide. At CTOS 2024, preliminary data from over 880 respondents across 40 countries revealed critical insights. Key…
Read MoreTANGENT: Emactuzumab in Tenosynovial Giant Cell Tumors
Treatment of Emactuzumab in Tenosynovial Giant Cell Tumors (TANGENT) Agents: Emactuzumab Phase III Status Open, recruiting Sponsor SynOx Therapeutics For further information please also consult ClinicalTrials.gov. This is a multicenter, phase 3, randomised, double-blind, placebo-controlled study, which aims to evaluate the efficacy and safety of emactuzumab for the treatment of patients with Tenosynovial…
Read More